WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2012129381) DEUTERATED PRELADENANT
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/129381    International Application No.:    PCT/US2012/030081
Publication Date: 27.09.2012 International Filing Date: 22.03.2012
IPC:
C07D 487/14 (2006.01), A61K 31/505 (2006.01), A61P 25/16 (2006.01), C07B 59/00 (2006.01)
Applicants: CONCERT PHARMACEUTICALS INC. [US/US]; 99 Hayden Avenue Suite 100 Lexington, Massachusetts 02421 (US) (For All Designated States Except US).
PANDYA, Bhaumik A. [US/US]; (US) (For US Only)
Inventors: PANDYA, Bhaumik A.; (US)
Agent: LAVOIE, Teresa A.; Fish & Richardson P.C. P.O. Box 1022 Minneapolis, Minnesota 55440-1022 (US)
Priority Data:
61/466,310 22.03.2011 US
Title (EN) DEUTERATED PRELADENANT
(FR) PRELADENANT DEUTÉRÉ
Abstract: front page image
(EN)This invention relates to novel 5 -amino-pyrazolo- [4,3-e] - 1, 2, 4 - triazolo [1, 5 - c] pyrimidines and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating Parkinson's diseases, other Parkinsonian disorders, anxiety, and other conditions that are beneficially treated by administering an adenosine A2A antagonist.
(FR)La présente invention concerne de nouvelles 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines et leurs sels pharmaceutiquement acceptables. La présente invention concerne également des compositions comprenant un composé de cette invention et l'utilisation de ces compositions dans des procédés de traitement de maladies de Parkinson, d'autres troubles de type parkinsoniens, de l'anxiété et d'autres pathologies qui sont avantageusement traitées par administration d'un antagoniste d'adénosine A2A.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)